VEJLE, Denmark—March 5, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, today announced that the United States Patent and Trademark Office (USPTO) has issued it two patents: U.S. Patent No. 10,925,853 and US 10,933,017 cover the use of cannabinoids within NordicCan’s oral dosage formats Zapliq Chewable Tablet and compressed chewing gum.
“We are pleased to be able to offer our B2B partners and consumers worldwide a wide range of safe, pleasant, efficient and user-friendly formats for cannabinoids. The patents are the result of many years of research and development in our laboratories and attest to our unique knowledge of combining oral delivery formats and cannabinoids,” said Jesper Neergaard, Senior Principal and Head of IPR at Fertin Pharma and NordicCan.
Patent No. 10,925,853, for “Oral Cannabinoid Tablet,” refers to delivery of cannabinoids to mucosal surfaces through Zapliq® fast liquefiable chewable tablet. Patent US 10,933,017, covering “tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers,” relates to a tableted chewing gum composition for oral administration of cannabinoids. The main objective of these technologies is to provide oral delivery dosages with cannabinoids that have a pleasurable mouthfeel through unique taste and texture.
For more information about this announcement, visit www.nordiccan.com
Jesper Nergaard, Senior Principal, Head of IPR at Fertin Pharma, JNR@fertin.com
Julie Malbaek, CEO – NordicCan A/S, JULM@fertin.com
About NordicCan A/S:
NordicCan A/S, a sister company of Fertin Pharma, develops and produces innovative cannabinoid containing products based on unique oral and intra-oral delivery systems. With a health focus, NordicCan defines its business scope within Wellness, Medicinal and Pharmaceutical approved cannabinoid containing formats. Fertin Pharma and NordicCan jointly have access to and mastery of the most comprehensive portfolio of intra-oral delivery systems globally. They own a wide range of patents covering several oral and intra-oral delivery technologies, which offer the patient and consumer efficient, pleasurable and convenient delivery formats.